MX2022016263A - Derivados de ciclobutil-urea. - Google Patents

Derivados de ciclobutil-urea.

Info

Publication number
MX2022016263A
MX2022016263A MX2022016263A MX2022016263A MX2022016263A MX 2022016263 A MX2022016263 A MX 2022016263A MX 2022016263 A MX2022016263 A MX 2022016263A MX 2022016263 A MX2022016263 A MX 2022016263A MX 2022016263 A MX2022016263 A MX 2022016263A
Authority
MX
Mexico
Prior art keywords
sup
cyclobutyl
urea derivatives
compounds
formula
Prior art date
Application number
MX2022016263A
Other languages
English (en)
Inventor
Romain Siegrist
Jens- Uwe PETERS
Jean- Philippe SURIVET
Olivier Bezencon
Caroline Deymier
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of MX2022016263A publication Critical patent/MX2022016263A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/26Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epidemiology (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a compuestos de la Fórmula (I) (ver Fórmula) Fórmula (I) donde X1, X2, X3, L, RX4, R1, R2A, R2B, R3, R4, R5 y R6 son como se describen en la descripción; a su preparación, a sus sales farmacéuticamente aceptables, a las composiciones farmacéuticas que contienen uno o más compuestos de la Fórmula (I) y al uso de tales compuestos como medicamentos, especialmente como abridores de KV7.
MX2022016263A 2020-06-25 2021-06-24 Derivados de ciclobutil-urea. MX2022016263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2020067903 2020-06-25
PCT/EP2021/067288 WO2021260090A1 (en) 2020-06-25 2021-06-24 Cyclobutyl-urea derivatives

Publications (1)

Publication Number Publication Date
MX2022016263A true MX2022016263A (es) 2023-02-09

Family

ID=76624055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016263A MX2022016263A (es) 2020-06-25 2021-06-24 Derivados de ciclobutil-urea.

Country Status (11)

Country Link
US (1) US20230303486A1 (es)
EP (1) EP4172140A1 (es)
JP (1) JP2023531500A (es)
KR (1) KR20230029813A (es)
CN (1) CN115702141A (es)
AR (1) AR122739A1 (es)
AU (1) AU2021295422A1 (es)
CA (1) CA3183298A1 (es)
MX (1) MX2022016263A (es)
TW (1) TW202216660A (es)
WO (1) WO2021260090A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023091554A1 (en) * 2021-11-19 2023-05-25 Icagen, Llc Novel heteroaryl-urea compounds as kv7.2 inhibitors
WO2023158584A1 (en) * 2022-02-15 2023-08-24 Icagen, Llc New bicyclopentane derivatives
WO2024121048A1 (en) * 2022-12-05 2024-06-13 Angelini Pharma S.P.A. Urea compounds as activators of potassium channels kv7.2/7.3 useful in the treatment of cns and pns disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017005044A (es) * 2014-10-24 2017-07-04 Ono Pharmaceutical Co Activador de canales de kcnq2-5.
EP3366683A1 (en) 2017-02-28 2018-08-29 Acousia Therapeutics GmbH Cyclic amides, acteamides and ureas useful as potassium channel openers
MD3755684T2 (ro) 2018-02-20 2023-11-30 H Lundbeck As Derivați de alcool ca deschizători ai canalelor de potasiu Kv7
WO2020163268A1 (en) 2019-02-06 2020-08-13 Eli Lilly And Company 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea derivatives as kcnq potentiators

Also Published As

Publication number Publication date
CA3183298A1 (en) 2021-12-30
AR122739A1 (es) 2022-10-05
CN115702141A (zh) 2023-02-14
TW202216660A (zh) 2022-05-01
AU2021295422A1 (en) 2023-02-23
EP4172140A1 (en) 2023-05-03
US20230303486A1 (en) 2023-09-28
JP2023531500A (ja) 2023-07-24
KR20230029813A (ko) 2023-03-03
WO2021260090A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
MX2022016263A (es) Derivados de ciclobutil-urea.
MX2022015260A (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer.
MX2023001379A (es) Derivados de piperidin-1-il-n-piridina-3-il-2-oxoacet amida utiles para el tratamiento de canceres deficientes en mtap y/o que acumulan mt a.
EP4299135A3 (en) Benzisoxazole sulfonamide derivatives
ES2187300A1 (es) Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
AP1739A (en) Azaindoles
UA94901C2 (ru) Антибактериальные производные пиперидина
MY147373A (en) Piperazine derivatives as antimalarial agents
BR0212829A (pt) Derivados de 1,8-naftiridina e seu uso para tratar diabetes e distúrbios relacionados
BG103969A (en) C-4"-substituted macrolide derivatives
ATE316083T1 (de) Adamantanderivate
MX2022015886A (es) Derivados de amidopirimidona.
WO2020113213A3 (en) Cyclic pantetheine derivatives and uses thereof
MX2022013223A (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2.
ATE386725T1 (de) Heterocyclylverbindungen
SE9901573D0 (sv) New compounds
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
MX2020013291A (es) Derivados de piridinilo alcoxisustituido como antagonistas del receptor lpa1 y su uso en el tratamiento de la fibrosis.
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
IL163608A (en) Sulfonanilides are conserved in their amino / amino acids and derivatives, their process, their pharmaceutical preparations, and their conjugated antibodies and their use in the preparation of drugs for the treatment of culture disorders
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
TW200740440A (en) Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient
SE9901572D0 (sv) New compounds
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
MX2021015727A (es) Derivados de piridin-3-ilo.